Secondary Logo

Institutional members access full text with Ovid®

Monamine Oxidase Inhibitors: Current and Emerging Agents for Parkinson Disease

Fernandez, Hubert H. MD*; Chen, Jack J. PharmD, BCPS, CGP*†

doi: 10.1097/01.wnf.0000240956.49315.be
Review Article
Buy

Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, for the symptomatic treatment of Parkinson disease (PD). Selegiline has demonstrated efficacy as monotherapy in patients with early PD (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism study), but evidence of selegiline efficacy as adjunctive treatment in levodopa-treated PD patients with motor fluctuations is equivocal. A new formulation of selegiline (Zydis selegiline) has been evaluated in 2 small, placebo-controlled studies as adjunctive therapy to levodopa. The Zydis formulation allows pregastric absorption of selegiline, minimizing first-pass metabolism, and thereby increasing selegiline bioavailability and reducing the concentration of amphetamine metabolites. Rasagiline is a selective, second-generation, irreversible MAO-B inhibitor, with at least 5 times the potency of selegiline in vitro and in animal models. Rasagiline has demonstrated efficacy in 1 large, randomized, double-blind, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson's Disease Outpatients) as initial monotherapy in patients with early PD, and in 2 large, controlled trials (Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "Off," Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily) as adjunctive treatment in levodopa-treated PD patients with motor fluctuations. Unlike selegiline, rasagiline is an aminoindan derivative with no amphetamine metabolites. A randomized clinical trial is underway to confirm preclinical and preliminary clinical data suggesting rasagiline has disease-modifying effects.

*Movement Disorders Center, Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, FL; and †School of Pharmacy, Loma Linda University, Loma Linda, CA.

Address correspondence and reprint requests to: Hubert H. Fernandez, MD, Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, FL 32610; E-mail: fernandez@neurology.ufl.edu.

© 2007 Lippincott Williams & Wilkins, Inc.